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age 71 vs. 62; P<0.0001), had a higher median b2 micro-
globulin (b2M) level both at diagnosis (5.5 vs. 3.7; p¼0.0002)
and auto-HCT (4 vs. 2.5; p<0.0001), and had a higher median
serum creatinine (Cr) at auto-HCT (1.3 vs. 1.05; p¼0.05). A
higher proportion of patients in MEL 140 were older than 65
with serum Cr> 2mg/dL. Therewas no signiﬁcant difference
in disease status or high-risk cytogenetics between the 2
groups. NCI CTCv3 > grade III non-hematologic toxicity was
not signiﬁcantly different between MEL 140 and MEL 200.
TRM at 100 days and at 1 year was 0% and 0.4% in MEL 140
and 200 (p¼1.0), respectively. Complete remission (CR) rates
in MEL 140 and MEL 200 were 16% and 29%, respectively
(p¼0.03). There was no signiﬁcant difference in (CR) + very
good partial remission (VGPR), or overall response (CR +
VGPR + PR) between MEL 140 and MEL 200. Median follow
up in surviving patients in MEL 140 and 200 was 7.6 and 25
months, respectively. Fifteen (24%) and 64 (25%) patients
died in MEL 140 and MEL 200 groups, respectively, with
>90% of deaths due to recurrent disease. Median PFS was
26.4 and 30.6 months in MEL 140 and MEL 200 groups,
respectively (p¼0.46). Median OS was 38.4 and 93.0 months
in MEL 140 and MEL 200 groups, respectively (p¼0.02).
However, there was no signiﬁcant difference in median PFS
(26 vs. 24.4 months) or median OS (38.6 vs. 62.2 months) in
patients older than 65 between MEL 140 and MEL 200.
Similarly, there was no signiﬁcant difference in median PFS
(24.5 vs. 31.3 months) or median OS (32.1 months vs. 69.3
months) in patients with a serum Cr > 2 mg/d between MEL
140 and MEL 200.
Conclusion: The dose of melphalan can be safely reduced to
140 mg/m2 in patients >65 or with renal insufﬁciency
without adversely impacting the overall response rate or PFS.460
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Background: Rituximab and inﬂiximab are two monoclonal
antibodies administered intravenously. Both medications are
generally administered over prolonged infusion times per
manufacturer guidelines in order to avoid infusion-related
toxicities. Rituximab is a chimeric anti-CD20 monoclonal
antibody used primarily for the treatment of EBV viremia,
autoimmune cytopenias and steroid refractory graft versus
host disease (srGVHD) in hematopoietic stem cell transplant
patients (HSCT) at Cincinnati Children’s Hospital Medical
Center (CCHMC). Recommended infusion times for ritux-
imab average 5-6 hours for the initial dose and 3-4 hours for
subsequent doses. Inﬂiximab is an anti-TNFa monoclonal
antibody used for srGVHD in HSCT patients at CCHMC. Rec-
ommended infusion of inﬂiximab is over 2-3 hours. Due to
the these infusion times, administration of both medications
is associated with decreased patient satisfaction, increased
health care costs and can also lead to compatibility/access
issues. Data exists to support rapid infusion (RI) adminis-
tration (over 1 hour) of these agents in non-HSCT adult pa-
tients, but data in pediatric HSCT patients is limited. Here wedescribe our experience with 1-hour infusions of rituximab
and inﬂiximab at CCHMC.
Methods: All HSCT patients who received rituximab or
inﬂiximab between March 2013 and October 2013 were
administered their ﬁrst dose by the standard manufacturer
guidelines. If patients tolerated the ﬁrst infusion they were
eligible to receive infusion of subsequent doses over 1 hour.
Patients were observed for infusion related reactions during
and for 30 minutes after infusion. Additionally, patients and
family members were advised to report any possible re-
actions within the 24 hours following infusion.
Results: Seven patients received 24 RI rituximab doses. The
median number of doses per patient was 3; (range 1-7). Five
patients were on corticosteroids as part of their baseline
regimen, no patients (including those not on baseline ste-
roids) received additional steroid pre-medication prior to
infusion. No adverse effects were reported with the RI of
rituximab. A total of 49 doses of RI inﬂiximab were admin-
istered to 8 patients. All 8 patients were on corticosteroids as
part of their daily regimen and no one received additional
steroid as pre-medication prior to their infusion. The median
number of inﬂiximab RIs per patient was 7.5 (range 1-17
doses). One patient receiving RI inﬂiximab experienced a
rash that resolved without intervention during the ﬁrst RI.
The patient received 4 additional RIs without side effects. No
additional side effects were seen in any other patients.
Conclusion: Rapid-infusions of rituximab and inﬂiximab
were safe and well tolerated when administered as the sec-
ond and subsequent infusion in a course of therapy. Patient
and family satisfaction were also improved.461
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Background: Chemotherapy followed by ﬁlgrastim is the
most common strategy used to mobilize cells for high dose
chemotherapy and autologous stem cell transplantation.
Unfortunately, this method does not always lead to adequate
cell collection in heavily pretreated patients with relapsed
malignancies or if multiple transplants are required. Plerix-
afor is an agent that has been studied in adults and has been
shown to be safe and efﬁcacious in the mobilization of pe-
ripheral blood stem cells (PBSC). Plerixafor is hematopoietic
stem cell mobilizer which inhibits the CXCR4 chemokine
receptor and blocks binding of its cognate ligand, stromal
cell-derived factor-1-alpha (SDF-1-alpha) which results in
leukocytosis and elevations in circulating hematopoietic
progenitor cells. Despite its use in adults, little evidence ex-
ists to support its use in children. Here we report our ob-
servations of 11 children at Cincinnati Children’s Hospital
Medical Center (CCHMC) who received plerixafor tomobilize
PBSC.
